Home/Filings/4/0000899243-23-008565
4//SEC Filing

Ally Bridge MedAlpha Master Fund L.P. 4

Accession 0000899243-23-008565

CIK 0001402479other

Filed

Mar 14, 8:00 PM ET

Accepted

Mar 15, 4:30 PM ET

Size

22.5 KB

Accession

0000899243-23-008565

Insider Transaction Report

Form 4
Period: 2023-03-13
Transactions
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+965,130$310,000965,130 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (965,130 underlying)
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+6,818,181$2,190,0006,818,181 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (6,818,181 underlying)
Transactions
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+6,818,181$2,190,0006,818,181 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (6,818,181 underlying)
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+965,130$310,000965,130 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (965,130 underlying)
Transactions
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+6,818,181$2,190,0006,818,181 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (6,818,181 underlying)
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+965,130$310,000965,130 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (965,130 underlying)
Transactions
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+6,818,181$2,190,0006,818,181 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (6,818,181 underlying)
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+965,130$310,000965,130 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (965,130 underlying)
Transactions
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+965,130$310,000965,130 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (965,130 underlying)
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+6,818,181$2,190,0006,818,181 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (6,818,181 underlying)
Transactions
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+6,818,181$2,190,0006,818,181 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (6,818,181 underlying)
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+965,130$310,000965,130 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (965,130 underlying)
Transactions
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+965,130$310,000965,130 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (965,130 underlying)
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+6,818,181$2,190,0006,818,181 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (6,818,181 underlying)
Yu Fan
10% Owner
Transactions
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+6,818,181$2,190,0006,818,181 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (6,818,181 underlying)
  • Purchase

    Pre-Funded Warrant (Right to Buy)

    2023-03-13$0.32/sh+965,130$310,000965,130 total(indirect: See footnote)
    Exercise: $0.00From: 2023-03-13Common Stock (965,130 underlying)
Footnotes (4)
  • [F1]Prior to the Issuer receiving certain required approval of the Issuer's stockholders (the "Requisite Stockholder Approval"), the Pre-Funded Warrant holders may only exercise up to the product of (i) the holder's pro rata portion of the Pre-Funded Warrants and (ii) 16,025,925, which is the number of shares equal to 19.99% of the Issuer's Common Stock outstanding on March 9, 2023.
  • [F2]The Pre-Funded Warrants do not expire.
  • [F3]These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.
  • [F4]These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.

Issuer

MedAvail Holdings, Inc.

CIK 0001402479

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001831963

Filing Metadata

Form type
4
Filed
Mar 14, 8:00 PM ET
Accepted
Mar 15, 4:30 PM ET
Size
22.5 KB